Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別)  
In DMSO JPY 17100
JPY 13600
JPY 48400
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(41)

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NEfEfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\BS4g2UUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NInXPXozPTl4MEK4Ni=>
KellyCis83 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLZSphKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN NX;iSlQ1OjV7NkCyPFI>
SK-N-AS MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW2RnFoUUN3ME2wMlI16oDLwsJihKkxNjB|IN88US=> NXTjRnJFOjV7NkCyPFI>
SK-N-ASCis24 NYDPTVM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\xPXF4UUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> NHHTUYEzPTl4MEK4Ni=>
U87 NGPtUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDWVExNTVyIN88US=> NWKzO5hFPDhiaB?= M4HRfYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTD3bIlkcCClYX6gZoUh\W6qYX7j[YQh[nlic3nsbYJqdmmw MkPTNlU4PTB{N{O=
HCT116 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPjNE42NTJwNTFOwG0> NGfoWmE1QMLiaNMg MWHJR|UxRTFwN{RCpOKyyqByLkKxxsDPxE1? M1n0U|I2PzR4N{[z
HT-29 NFzGOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSwMlUuOi53IN88US=> M{HjVFQ5yqCqwrC= NGXGSopKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= Mme5NlU4PDZ5NkO=
Caco2 NWj3ZnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTUSYUxNjVvMj61JO69VQ>? M4XNe|Q5yqCqwrC= MXrJR|UxRTdwMkdCpOKyyqBzLk[4xsDPxE1? MVuyOVc1Pjd4Mx?=
COLO 205 M2W1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KycVAvPS1{LkWg{txO M1TvOFQ5yqCqwrC= NFfrWHdKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= NVPOVpN2OjV5NE[3OlM>
SW480 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rsNFAvPS1{LkWg{txO NV7HfHFbPDkEoHlCpC=> MkC4TWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M{jTcVI2PzR4N{[z
HEK293T NXT4enBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfMemJmOS13IN88US=> NFXLSWg1QMLiaNMg MnnWTWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP MofONlU4PDZ5NkO=
Hep3B  NXTCV5VITnWwY4Tpc44hSXO|YYm= M3XjRlExKM7:TR?= M2LQe|Q5yqCqwrC= NHPHVGVz\WS3Y3XzJJRp\SCnbnjhcoNqdmdiZX\m[YN1KG:oIFLNVE03 M3q0SFI2PjN|NU[0
Hep3B  M122TWZ2dmO2aX;uJGF{e2G7 MlfoNE4yNTFyIN88US=> Mm\kNlQhcA>? Mlznd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBp\XClaXTpckBuWk6D M2fpZlI2PjN|NU[0
HEK293 NXX2d|N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fZc2lEPTB;Nz6xOOKhyrIEoECuN|bDqM7:TR?= MVeyOVYxOzF{Mh?=
DU145 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTkfW5rUUN3ME2yMlI5yqEEsdMgNE4xPMLizszN NIXEdIUzPTZyM{GyNi=>
HCT15 NYrFd4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? MYWyOVYxOzF{Mh?=
T47D NETidXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jMO2lEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= MWWyOVYxOzF{Mh?=
SMMC-7721 NYTkN3ByTnWwY4Tpc44hSXO|YYm= MWi0NEDPxE1? M{\ZN|Q5KGh? NYL2[|VYTE2VTx?= NHz0e3hqdmS3Y3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdg>? M{D4N|I2PTR2M{[x
MDA-MB-231 NGH1No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLGWm84OsLiaB?= MmnoTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? MYWyOVQ5PjJzOR?=
MCF-7 NVPBO4poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\uRVczyqCq MVrJR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? M4jEVlI2PDh4MkG5
Jurkat MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HLOFczyqCq NVjlfVFKUUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= NY\tWGw5OjV2OE[yNVk>
HeLa MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPyNW9uPzMEoHi= NXK5SoVCUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= M1;kO|I2PDh4MkG5
MCF7  NF3nd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkW2OU0yODBizszN MXG3JIQ> NELRUYlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFTOcXEzPTR5Mk[xPS=>
K562 NGj2OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;1OlJGPzMEoHi= MWLJR|UxRTBwMkpCpO69VQ>? NFPHd2QzPTJ6Mk[1Ny=>
K/VP.5 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LQS|czyqCq MkThTWM2OD12LkpCpO69VQ>? MkKyNlUzQDJ4NUO=
SH-EP  M{DR[mZ2dmO2aX;uJGF{e2G7 NWiwZZdlOjEEoN88[{9udA>? NXvzSpZKOjUEoHi= MWrpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS NETZSFIzPTJ4MUm4NS=>
SCC25 M4jubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qzb|I1yqCq NUXKT3NJUUN3ME20N{4{yqEEsdMgNU4yOsLizszN NIfWVFMzPTJ{MEeyPS=>
CAL27 NFLPOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[yOOKhcA>? NX\q[|N7UUN3ME21Nk4yyqEEsdMgNU4xQcLizszN NWXk[I04OjV{MkC3Nlk>
FaDu NXPhWJlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzPdllFOjUEoHi= M3LTemlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= MV:yOVIzODd{OR?=
SCC25 NGjRcFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:0POKhcA>? NELDcppKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN MorLNlUzOjB5Mkm=
CAL27 NGPCUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4[4lRPDkEoHi= NYXPbIpmUUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> MXuyOVIzODd{OR?=
FaDu MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f2eVQ5yqCq NGPTOmtKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= M1L6cVI2OjJyN{K5
SCC25 M4XwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\wSVczyqCq MorLTWM2OD16LkSxxsDDucLiMT6xNeKh|ryP NXHqbG9jOjV{MkC3Nlk>
CAL27 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq3NuKhcA>? NVXke4J4UUN3ME20MlI4yqEEsdMgNU4yPMLizszN MkntNlUzOjB5Mkm=
FaDu NXzVZlVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfwdoc4OsLiaB?= MX3JR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? MXuyOVIzODd{OR?=
MCF-7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;XUVQ5yqCqwrC= NFe4SYJFVVOR NGDyfJhKSzVyPUeuNuKhyrIEoECuPOKh|ryP NEfTW3czPTJzNkO3PC=>
T-47D NFKzeWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW2OFjDqGkEoB?= NXqyNW1sTE2VTx?= NVzSTIJKUUN3ME23MlfDqMLzwrCwMlfDqM7:TR?= Mn7sNlUzOTZ|N{i=
MDA-MB-231 Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljKOFjDqGkEoB?= MYfEUXNQ NGXiPJdKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= M3vaUVI2OjF4M{e4
DU145 NV7ETodrSXCxcITvd4l{KEG|c3H5 NGTvZmIyOC1zMECg{txO MYe4JIg> MmXaSG1UVw>? M1fjPIlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MXSyOVE1QTZ6MR?=
DU145 stem-like NUXSNXc4SXCxcITvd4l{KEG|c3H5 MnjONVAuOTByIN88US=> NF7mZVk5KGh? NETNdlVFVVOR MkfYbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mnu4NlUyPDl4OEG=
DU145 Mk\DSpVv[3Srb36gRZN{[Xl? M2DjV|ExNTFyMDFOwG0> NUL4SmRsOiCq MVHEUXNQ MXjpcoNz\WG|ZYOgeIhmKHCFSFuxJIV5eHKnc4Ppc44h[W6mIHTlZ5Jm[XOnczD0bIUheEOKS{Gg[ZhxemW|c3nvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXyyOVE1QTZ6MR?=
DU145 stem-like NVS4[5BwTnWwY4Tpc44hSXO|YYm= NHnjUoIyOC1zMECg{txO NYL3XIVkOiCq NGfiN4NFVVOR NHqxVZpqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NH3SOlYzPTF2OU[4NS=>
UW228-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVni[2xFOC5yMT2zNFAh|ryP NV;RdJlIPDhiaB?= MlLnSG1UVw>? MWLJR|UxRTBwOUpCpO69VQ>? NIe3cmkzPTFzOUG4OS=>
NSCs MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrLPZkxNjBzLUOwNEDPxE1? MlTZOFghcA>? NGK3RndFVVOR MUnJR|UxRTBwMz2zxsDPxE1? NInCNJczPTFzOUG4OS=>
MKL-1  MVfGeY5kfGmxbjDBd5NigQ>? NF:0TXQyOC1zMECwJI5O M1S2O|Qh\A>? Mm[ybY5lfWOnczD0bIUhcW6mdXP0bY9vKG:oIF3IR{1KKGW6cILld5Nqd25? M3G0UFI2OTF4N{W0
MCF7 EV M1vjRWZ2dmO2aX;uJGF{e2G7 M1:wbVExNTFyMDFOwG0> M3;6clLjiImq MWPpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> NHKzS3YzPTB6OEKwNy=>
MCF 7BMI1 NV\6cYJYTnWwY4Tpc44hSXO|YYm= MUmxNE0yODBizszN NYHvTVZPOuLCiXi= NUDOTFhIcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NWfMepBkOjVyOEiyNFM>
MCF7 EV Mn\sSpVv[3Srb36gRZN{[Xl? MnzTNVAuOTByIN88US=> NHTYZXoz6oDLaB?= MWrFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= M2n3RVI2ODh6MkCz
MCF7 BMI1 MnS1SpVv[3Srb36gRZN{[Xl? MYGxNE0yODBizszN NH\6RXIz6oDLaB?= MkizSXRQWCCrbnT1Z4V{KEGWTTDhZ5RqfmG2aX;u MW[yOVA5QDJyMx?=
HepG2 NF7ZdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XWc2ROW00EoB?= NFX1T4lKSzVyPUOwMlE3yqEEsdMgNE42OMLizszN NH72NoMzPTB5OEOxNS=>
MOLT-3 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfDfHNFVVORwrC= NI[zUndKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> Ml;3NlUxPzh|MUG=
HT1080 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3TWHZkOS1zMECg{txO NHHrcZA1NzJ2L{S4JIg> NFHmVJRFVVORwrC= NYXIZoxucW6mdXPld{Bk\WyuIHTlZZRpKHOrZ37p[olk[W62bImgbY4h[SC4ZYL5JIxwfyClb37j[Y51emG2aX;u MWCyOVA4QDB4NB?=
HT1080 NF;Vd3FHfW6ldHnvckBCe3OjeR?= MXWwMlAxODFvMUCwJO69VQ>? NXvGR4ZYOS1{NDDo M3vZ[mROW00EoB?= MlrobY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NFXsWYgzPTB5OEC2OC=>
HT1080 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPrVnYxNjByMEGtNVAxKM7:TR?= NVXHcooxOjRiaB?= MYTEUXNQyqB? MYPjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| MYWyOVA4QDB4NB?=
HD-MY-Z NYLocIM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW2ZWpNOjRxNEivO|IhcA>? MX\JR|Ux97zgMUCwJO69VQ>? NEXEdIkzPTB2OEKzOi=>
DOHH-2 M{TIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7DUXEzPCCq MX3JR|Ux97zgMUCwJO69VQ>? MWmyOVA1QDJ|Nh?=
DOHH-2 NV2xUFBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nyOVQ5KGh? NIG4R45KSzVyPUG5MlnDqM7:TR?= NF\5VVQzPTB2OEKzOi=>
DOHH-2 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\BclczKGh? MUPJR|UxRTYEoN88US=> MnTYNlUxPDh{M{[=
REH NFW4Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPjNlQhcA>? NVfrXYs2UUN3ME2wMlAzP8LizszN MmTHNlUxPDh{M{[=
REH NI\UdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrKeod6PDhiaB?= NY\aWGZrUUN3ME2wMlAyPMLizszN MV2yOVA1QDJ|Nh?=
REH M1L3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWS3NkBp MXrJR|UxRTBwMEG1xsDPxE1? NXq2[lcxOjVyNEiyN|Y>
HH NXH6WIJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfYSmlUOjRiaB?= M1fiWWlEPTB;MUC0MlfDqM7:TR?= NFvrbIUzPTB2OEKzOi=>
HH M{nBb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfiOFghcA>? M17wdWlEPTB;NEiuOuKh|ryP M3jpPVI2ODR6MkO2
HH Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\yOm44OiCq NYT6T2l6UUN3ME2xOE44yqEQvF2= NGDLNGYzPTB2OEKzOi=>
HuT-78 NITX[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPKNlQhcA>? NEH0RVBKSzVyPUmuN:Kh|ryP NI\EeokzPTB2OEKzOi=>
HuT-78 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV20W29EPDhiaB?= NUDNbZZIUUN3ME20MlPDqM7:TR?= MmPrNlUxPDh{M{[=
HuT-78 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG0R4Q4OiCq M1zVe2lEPTB;ND6yxsDPxE1? MkL4NlUxPDh{M{[=
OPM-2 NFXub|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW3W2UzPCCq M2C5O2lEPTB;MkSuNeKh|ryP NULxZXpnOjVyNEiyN|Y>
OPM-2 NIK1SJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDL[oM1QCCq M2rUbWlEPTB;NNMg{txO M3HVUFI2ODR6MkO2
OPM-2 M{[zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTIO|IhcA>? MnLkTWM2OD1zLkRCpO69VQ>? NIfNO48zPTB2OEKzOi=>
RPMI-8226 NV7KNo5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDRcWMzPCCq NHG0UYtKSzVyPUGwOk43yqEQvF2= MmD5NlUxPDh{M{[=
RPMI-8226 M1P1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmPVk6PDhiaB?= M{KxcmlEPTB;OUGuNeKh|ryP MlPKNlUxPDh{M{[=
RPMI-8226 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvBc5NpPzJiaB?= NVz4cJBLUUN3ME2xOE46yqEQvF2= NV\zTmRuOjVyNEiyN|Y>
U-266 NECyc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3KzVFI1KGh? NWPJ[5B3UUN3ME24Ok4zyqEQvF2= M2\GWFI2ODR6MkO2
U-266 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDadZBFPDhiaB?= NFzvPVVKSzVyPU[4MlTDqM7:TR?= NUjY[Xl{OjVyNEiyN|Y>
U-266 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV2yUnl5PzJiaB?= MnfYTWM2OD1{Nz60xsDPxE1? M2fXclI2ODR6MkO2
Kelly NWjGO2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzmdJNlOC1zMDFOwG0> NXjhfHNsPzMEoHi= Mm[4TWM2OD1zLkWxPOKh|ryP M3L0S|I2ODB6OUCw
SH-SY5Y  MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCxSlY{OC1zMDFOwG0> MUi3NuKhcA>? NW\XXYt4UUN3ME2wMlc2PMLizszNxsA> NEmwWY8zPTByOEmwNC=>
SK-N-AS Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi1SnoxNTFyIN88US=> NILQfJo4OsLiaB?= NFzpWFNKSzVyPUGuO|EzyqEQvF5CpC=> NWXrd4VDOjVyMEi5NFA>
SK-N-DZ NVzSVGs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrkfmJzOC1zMDFOwG0> NW\afnVNPzMEoHi= M{G5bmlEPTB;NT60PFXDqM7:TR?= NXztS2hPOjVyMEi5NFA>
HepG2 NYLEUo5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m0dlQ5yqCq M1:3e2ROW00EoB?= NYXiR2Q2UUN3ME2xN{43PcLiwsJCpFAvQTMEoN88US=> Mn3ZNlQ6QTZzM{[=
A549 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3tbIw1QMLiaB?= MX7EUXNQyqB? NGnLV5JKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> NYnze4E1OjR7OU[xN|Y>
MCF7 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLIdHQ1QMLiaB?= MUnEUXNQyqB? M1PRcmlEPTB;OEGuNFnDqMLzwrCxOE4zOcLizszN NW\0fZZYOjR7OU[xN|Y>
HL-60  NGXiUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[3NuKhcA>? Mk\LTWM2OD1yLkGy5qCG|ryP NH;wR2gzPDl7M{CxOC=>
HL-60[R] NFnNOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zMZVczyqCq M1zPUGlEPTB;Mz6xNwKBjc7:TR?= M{f6TVI1QTl|MEG0
MIAPACA MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfHTVUxRTFwMzFCtUAxNjB|IN88US=> MlvmNlQ6PTN6MkG=
MCF-7 M2XkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXHTVUxRTBwMkWgxtEhOC5zIN88US=> MYOyOFk2Ozh{MR?=
HeLa NGnZcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4njcGdKPTB;MD62OEDDuSByLkSg{txO NXqzV3oyOjR7NUO4NlE>
MO59K  MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljrO{Bl NHvUWVZKSzVyPUCuNVfjiIYQvF2= MXOyOFk2OzV4MR?=
MO59J NVu0VZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXy3JIQ> M{\hS2lEPTB;MD6x5qCG|ryP MkDXNlQ6PTN3NkG=
ME 180 NV:zPVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6yZolEPDkEoHlCpC=> NUO0U|lMUUN3ME24MlnDqMLzwrCwMlPjiIYQvF2= M2rJSFI1QTV|MEK3
MCF-7 M4\sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS0POKhcMLi NXfsbI5vUUN3ME2yN{46KMLzIECuN-KBjc7:TR?= MXuyOFk2OzB{Nx?=
HeLa MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;wVnM1QMLiaNMg NWD5R5ZqUUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= M1PV[FI1QTV|MEK3
MDA-MB-453 M1;XZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ZXJQ{PDkEoHlCpC=> MUTJR|UxRTF{LkWgxtEhOC56NfMAie69VQ>? M1XkdlI1QTV|MEK3
MDA-MB-231 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm0POKhcMLi M3X5b2lEPTB;MkSuNlIhyrFiMj65OQKBjc7:TR?= NYXm[5BEOjR7NUOwNlc>
PC-3 NHrMU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;iOFjDqGkEoB?= M4C1eGlEPTB;MUSuOEDDuSB|LkKz5qCG|ryP NVfwUVhZOjR7NUOwNlc>
HT-29 NV7Dc5FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe0POKhcMLi MlXXTWM2OD1{MT60OUDDuSB|Lki35qCG|ryP MYGyOFk2OzB{Nx?=
BGC-823 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWe0POKhcMLi M1:2TWlEPTB;NEOuO|QhyrFiNT6xN-KBjc7:TR?= Ml21NlQ4QTN6N{e=
HeLa Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfyWpg1QMLiaNMg MoGyTWM2OD1{MEmuPVAhyrFiMUOuOFIh6oDHzszN Mke3NlQ4QTN6N{e=
A549 M33pUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKzOFjDqGkEoB?= NV2weVNmUUN3ME2xN|kvPTRiwsGgO{4xPeLChd88US=> M3f3WVI1Pzl|OEe3
HK-2 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi0POKhcMLi NX\FR5hJUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= MXuyOFc6Ozh5Nx?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+H2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
in solvent
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID